Patents Assigned to UNIVERSITÉ D'AVIGNON
-
Patent number: 11283304Abstract: A rectenna device (400) for converting incident light to electrical energy is disclosed. The rectenna device comprises a substrate (402), a first metallic layer (404) having a predefined thickness deposited on top of the substrate, a rectifying element (405) deposited on top of the first metallic layer, a second metallic layer (408) deposited on top of said rectifying element and configured to collect electromagnetic waves of the incident light and to couple it into plasmonic waves within the rectenna device, the second metallic layer comprising an array of a plurality of metallic patches (410) spaced from each other according to a predefined spacing, each metallic patch having predefined dimensions.Type: GrantFiled: November 28, 2018Date of Patent: March 22, 2022Assignees: UNIVERSITE D'AIX-MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ECOLE CENTRALE DE MARSEILLE, UNIVERSITE DE TOULONInventors: David Duche, Ludovic Escoubas, Ujwol Palanchoke, Jean-Jacques Simon, Teodor Silvius Balaban
-
Patent number: 11278543Abstract: The present invention relates to the general field of treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the treatment of immunosuppressive activity namely autoimmune diseases and graft rejection. In particular, the invention relates to an inhibitor of the activity or the formation of the PP1/GADD34 complex for the treatment of a condition requiring an immunosuppressive activity or an anti-inflammatory activity.Type: GrantFiled: December 15, 2015Date of Patent: March 22, 2022Assignees: INSERM, UNIVERSITE D'AIX MARSEILLE, CNRSInventor: Philippe Pierre
-
Patent number: 11278733Abstract: This magnetic emission device includes an antenna and further includes a device configured to select one of a plurality of predefined portions of the antenna and to connect the selected portion to a current-generating device in order both to cause the current to pass through the selected portion of the antenna so as to radiate a magnetic field, and to prevent the current from passing outside of the selected portion of the antenna.Type: GrantFiled: April 16, 2019Date of Patent: March 22, 2022Assignees: Université d'Aix Marseille, Centre National de la Recherche Scientifique, Ecole Centrale de Marseille, Assistance Publique—Hôpitaux de Marseille, Multiwave Technologies AGInventors: Stefan Enoch, Redha Abdeddaim, Éric Émile David Guedj, Raphaëlle Richieri Le Rouzic, Megdouda Benamara, Marie Coralie Bultot, Michael Kefeder, Tryfon Antonakakis, Elodie Georget-Paris, Fouad Fezari
-
Patent number: 11277095Abstract: A method for producing a multicoloured optoelectronic device is provided as well as a device produced with that method. An electrically conducting substrate including a first and second portion adjacent to the first portion is obtained. Then a first photoactive material having optical properties in a first frequency range is deposited on the first portion and a second photoactive material differing from the first photoactive material having optical properties in a second frequency range is deposited on the second portion, the first photoactive material contacting the second photoactive material, forming a photoactive layer of the multicoloured optoelectronic device.Type: GrantFiled: February 23, 2018Date of Patent: March 15, 2022Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ D'AIX-MARSEILLEInventors: Jörg Ackermann, Sadok Ben Dkhil, Olivier Margeat, David Duché, Ludovic Escoubas, Jean-Jacques Simon, Christine Videlot-Ackermann
-
Patent number: 11274160Abstract: The present invention relates to a new antibody anti-nectin-4. Nectin-4 is a tumor-associated antigen overexpressed in several cancers and notably in 30%, 49% and 86% of breast, ovarian and lung carcinomas, respectively, which are tumors of bad prognosis. Treatments remain still elusive. That's why the inventors developed a new targeted therapy based on an antibody having specificity to nectin-4 (called 14A5.2 mab). Indeed, the inventors selected this antibody for its intrinsic prophylactic anti-metastatic properties and also for the treatment of localized primary and metastatic cancer. More, the 14A5.2 mab could be indicated for the treatment of cancer resistant to ASG-22ME (from Astellas company). Thus, the invention relates to the 14A5.2 mab and its uses thereof.Type: GrantFiled: March 1, 2018Date of Patent: March 15, 2022Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, INSTITUT JEAN PAOLI & IRENE CALETTES, CENTRE NATIONALE DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'AIX MARSEILLEInventor: Marc Lopez
-
Patent number: 11271230Abstract: Disclosed is a method for electrical supply of an apparatus by a system including an intermittent electrical source, electrical storage unit, a fuel cell, and an electrochemical unit for generating the fuel. The method includes steps of: determining a power balance of the system depending on the power consumed by the apparatus and supplied by the intermittent electrical source; receiving data representative of the stability of the power balance during a safety period; controlling the fuel cell and the electrochemical unit: to activate the electrochemical unit if the power balance is greater than a first threshold and the data are not characteristic of a subsequent decrease in the power balance; activating the fuel cell if the power balance is less than a second threshold, which is less than the first threshold, and the data are not characteristic of a subsequent increase in the power balance.Type: GrantFiled: May 30, 2017Date of Patent: March 8, 2022Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ D'OrlÉANSInventors: Pascal Brault, Cédric Grolleau, Samuel Rouxel, Serge Gasnier, Amael Caillard, Thomas Lecas
-
Publication number: 20220054424Abstract: The treatment of cancer using platinum-based compounds includes certain drawbacks such as biocompatibility, loading efficacy, leakage of drugs during storage and in the bloodstream, more particularly due to the nature of the nanocarriers for platinum delivery. A nanosystem that allows improving platinum-based drug in vivo performance, kinetics and efficacy. In particular, nanoparticles useful as drug delivery system, these nanoparticles being formed from at least: (a) platinum-based drug, (b) poly-L-arginine, and (c) hyaluronic acid. Particularly, these nanoparticles have been tested in terms of entrapment efficiency and also carried out in vitro experiments in 2D cell culture (viability studies on B6KPC3, A549 and HT-29 cells) and 3D cell model (spheroids made of HTC-116) and in vivo experiments (by injecting intravenously to mice the nanoparticles or comparative oxaliplatin solution) to prove their efficiency.Type: ApplicationFiled: September 16, 2019Publication date: February 24, 2022Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -, UNIVERSITE D'ANGERS, CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERSInventors: Giovanna LOLLO, Jean-Pierre BENOIT, Marie BRACHET - BOTINEAU
-
Publication number: 20220039736Abstract: The invention relates to modulating epileptogenicity in a brain of an epileptic patient. The method according to the invention comprises the steps of: providing a virtual brain; providing a model of an epileptogenic and of a propagation zones and loading said models in the virtual brain to create a virtual epileptic brain; acquiring data of the brain of the epileptic patient; identifying, in said data, a location of at least one possible epileptogenic zone; fitting the virtual epileptic brain against the data acquired from the epileptic patient and parametrizing said at least one possible epileptogenic zone in the virtual epileptic brain as an epileptogenic zone; and simulating, within the virtual epileptic brain, the effect of a network modulation mimicking a clinical intervention of the brain of the patient.Type: ApplicationFiled: October 25, 2021Publication date: February 10, 2022Applicants: UNIVERSITE D'AIX MARSEILLE (AMU), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ASSISTANCE PUBLIQUE - HOPITAUX DE MARSEILLE (AP-HM), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Viktor Jirsa, Christophe Bernard, Fabrice Bartolomei, Maxime Guye
-
Publication number: 20220033756Abstract: The invention describes a device (10) for dispensing microbubbles (30) for cell sonoporation, comprising: a tube configured to receive a vial (20) containing a solution (26) of microbubbles (30), at least two catheters (11, 12) arranged inside the tube and opening into the vial (20) when the latter is received by the tube, wherein, when the first catheter (11) is connected to a first air injection source, air can be injected into the vial (20) via the first catheter so as to generate an overpressure therein, the microbubbles (30) contained in the vial (20) entering the second catheter (12) and moving toward its second end (122). The invention also relates to a sonoporation device, a sonoporation process and a computer program product.Type: ApplicationFiled: September 18, 2019Publication date: February 3, 2022Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'ORLEANSInventors: Anthony DELALANDE, Matthias LEBERTRE, Michaël DELALANDE, Chantal PICHON
-
Patent number: 11236367Abstract: The present invention relates to the identification of a new class of fatty acid decarboxylases and its uses, in particular for producing alkanes/alkenes from fatty acids.Type: GrantFiled: May 19, 2017Date of Patent: February 1, 2022Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'AIX-MARSEILLEInventors: Frederic Beisson, Damien Sorigue, Bertrand Legeret, Stephan Cuine, Stephanie Blangy, Gilles Peltier
-
Patent number: 11225481Abstract: This invention relates to xanthine derivative compounds that are inhibitors of BET bromodomains proteins, the method of preparation thereof and applications thereof.Type: GrantFiled: December 27, 2016Date of Patent: January 18, 2022Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ D'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTESInventors: Xavier Morelli, Sébastien Combes, Jean-Claude Guillemot, Stéphanie Betzi, Yves Collette, Philippe Roche, Adrien Lugari, Sabine Milhas, Brigitt Raux, Iuliia Voitovich
-
Patent number: 11202973Abstract: The present invention relates to the field of upgrading biomass, in particular algal biomass, and more specifically the present invention relates to a method for extracting water-soluble compounds from microalgae and/or cyanobacteria, as well as the product obtained by this method and the uses of same, in particular in the food industry or as food supplements.Type: GrantFiled: June 15, 2018Date of Patent: December 21, 2021Assignees: ALGAMA, UNIVERSITÉ D'AVIGNON ET DES PAYS DE VAUCLUSEInventors: Farid Chemat, Maryline Abert Vian, Léa Vernes, Thomas Felice, Mathieu Goncalves Alves
-
Patent number: 11199542Abstract: The invention relates to a method for labeling specifically living bacteria, comprising the steps of: a) incubating said bacteria of said sample with at least one modified monosaccharide compound comprising a first reactive chemical group capable to chemically react with a second reactive group, so that a residue bearing said first reactive group is incorporated into the envelope of such bacteria, and b) contacting said modified monosaccharide residue incorporated within the envelope of the bacteria with a labeling molecule comprising a said second reactive group, for generating the chemical reaction of said first reactive group with said second reactive group, characterized in that said modified monosaccharide compound has the following formula (I), or a salt thereof: Wherein —A, B and C can be independently H, OH, NH2, OH and NH2 being substituted or not by protecting groups thereof and —D is an alkyl chain in C2 to C4, each carbon being substituted or not by OH or NH2, OH and NH2 being substituted or not bType: GrantFiled: May 3, 2016Date of Patent: December 14, 2021Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'AIX-MARSEILLEInventors: Sam Dukan, Boris Vauzeilles, Jordi Mas Pons, Aurélie Baron
-
Publication number: 20210382290Abstract: According to one aspect, the invention relates to a device (200) for transporting and controlling light beams comprising a light guide (40) comprising a bundle (50) of uncoupled single-mode optical fibers (Fi), each single-mode optical fiber (Fi) being intended to receive an elementary light beam (B1i) at a proximal end and to emit a light beam (B2i) at a distal end, said bundle of single-mode optical fibers comprising, in operation, a minimum radius of curvature corresponding to a maximum curvature of the bundle of fibers.Type: ApplicationFiled: September 10, 2019Publication date: December 9, 2021Applicants: Centre National de la Recherche Scientifique, Université d'Aix-Marseille, Université de Lille, Ecole Centrale de MarseilleInventors: Hervé Rigneault, Géraud Bouwmans, Esben Andresen, Siddarth Sivankutty, Viktor Tsvirkun, Olivier Vanvincq
-
Publication number: 20210381985Abstract: According to one aspect, the present description relates to a device for detecting an SRS resonant non-linear optical signal induced in a sample. The device comprises a light source configured for emitting a first train of pump pulses at a first angular frequency and a second train of Stokes pulses at a Stokes second angular frequency, and first and second amplitude modulators configured to amplitude modulate the train of pump pulses at a first modulation frequency and the train of Stokes pulses at a second modulation frequency different from the first modulation frequency, respectively.Type: ApplicationFiled: June 4, 2021Publication date: December 9, 2021Applicants: LIGHTCORE TECHNOLOGIES, Centre National de la Recherche Scientifique, UNIVERSITÉ D'AIX MARSEILLE, Ecole Centrale de MarseilleInventors: Hervé Rigneault, Sandro Heuke
-
Patent number: 11191476Abstract: The method of modulating epileptogenicity in a brain of an epileptic patient includes: providing a virtual brain; providing a model of an epileptogenic and of a propagation zones and loading the model in the virtual brain to create a virtual epileptic brain; acquiring data of the brain of the epileptic patient; identifying, in the data, a location of at least one possible epileptogenic zone; fitting the virtual epileptic brain against the data acquired from the epileptic patient and parametrizing the at least one possible epileptogenic zone in the virtual epileptic brain as an epileptogenic zone; and simulating, within the virtual epileptic brain, the effect of a network modulation mimicking a clinical intervention of the brain of the patient.Type: GrantFiled: July 18, 2016Date of Patent: December 7, 2021Assignees: UNIVERSITE D'AIX MARSEILLE (AMU), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ASSISTANCE PUBLIQUE—HOPITAUX DE MARSEILLE (AP-HM), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Viktor Jirsa, Christophe Bernard, Fabrice Bartolomei, Maxime Guye
-
Patent number: 11187705Abstract: The invention relates to a method for labeling specifically living microorganisms in a sample comprising microorganisms, the method comprising the steps of: a) incubating said microorganisms of said sample with at least one modified monosaccharide compound comprising a first reactive chemical group capable to chemically react with a second reactive group, so that a residue bearing said first reactive group is incorporated into such microorganisms, and b) contacting said residue incorporated in the microorganisms, with a labeling molecule comprising a said second reactive group, for generating the chemical reaction of said first reactive group of said residue incorporated within said living microorganisms with said second reactive group of said labeling molecule, resulting in a covalent link, characterized in that the said modified monosaccharide compound has the following formula (I?), or a salt thereof: —X can be O, NH or S, preferably O and NH, and —R1 and R2 can be independently H, OH, NH2, OH and NH2 beinType: GrantFiled: May 3, 2016Date of Patent: November 30, 2021Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'AIX-MARSEILLE, UNIVERSITE PARIS-SACLAYInventors: Sam Dukan, Boris Vauzeilles, Jordi Mas Pons, Aurélie Baron
-
Patent number: 11180556Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.Type: GrantFiled: April 23, 2018Date of Patent: November 23, 2021Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, Universite Claude Bernard—Lyon 1, Centre Leon BerardInventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
-
Patent number: 11180510Abstract: The present invention relates to a compound having the following formula (I): (I) wherein: —R is a (C1-C6)alkyl group; —R? is preferably H; —Ar is a (C5-C12)arylene radical; —X1 is —C(?O)—or —SO2—; and —R? is chosen from the group consisting of possibly substituted (C1-C6)alkyl, heteroaryl, (C5-C12)aryl, and (hetero)cycloalkyl groups, or a pharmaceutically acceptable salt and/or tautomeric form thereof, or its racemates, diastereomers or enantiomers.Type: GrantFiled: November 6, 2018Date of Patent: November 23, 2021Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ D'AIX-MARSEILLE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Stéphane Betzi, Sébastien Combes, Yves Collette, Laurent Hoffer, Xavier Morelli, Brigit Raux, Philippe Roche, Iuliia Voitovich
-
Patent number: 11165027Abstract: A compound represented by the following formula (1) is an excellent near-infrared emitter. R1 to R6 are H or a substituent and R7 is represented by the following formula (2). Ar11 is an aryl group, R11 is a substituent other than an aryl group and n11 is 1 or more.Type: GrantFiled: February 21, 2018Date of Patent: November 2, 2021Assignees: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'AIX-MARSEILLEInventors: Jean-Charles Ribierre, Sangarange Don Atula Sandanayaka, DaeHyeon Kim, Chihaya Adachi, Anthony D'Aleo, Frederic Fages, Elena Zaborova